Biogen Aktie - IDP

Rendering Error

Professionelle Tools für Privatanleger.

Premium

Current Price

132,45

Gebot

131,90

Fragen

132,40

Volumen

913

130,20 Tagesbereich 140,10

124,25 52-Wochen-Bereich 219,70

Marktkapitalisierung

19,387B

Handelsende

139,35

Handelsbeginn

139,00

Letzte Trade

132.44999

Letzter Handelszeitpunkt

19:59:17

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

1.017

Ausgegebene Aktien

146.374.937

Dividendenrendite

Kurs-Gewinn-Verhältnis

12,94

Gewinn pro Aktie (EPS)

11,15

Erlöse

9,68B

Nettogewinn

1,63B

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.biogen.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker IDP. The last closing price for Biogen was 139,35 €. Over the last year, Biogen shares have traded in a share price range of 124,25 € to 219,70 €.

Biogen currently has 146.374.937 shares in issue. The market capitalisation of Biogen is 20,40 € billion. Biogen has a price to earnings ratio (PE ratio) of 12.94.

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-3.90001	-2.86029336267	136.35	144.85	130.19999	1285	138.07590039	DE
4	-4.80001	-3.49727504554	137.25	144.85	124.25	1605	132.95434095	DE
12	-10.15001	-7.11781907433	142.6	150.19999	124.25	1017	135.82073225	DE
26	-48.10001	-26.6408252562	180.55	182.1	124.25	920	146.93805585	DE
52	-70.75001	-34.8179183071	203.2	219.7	124.25	752	167.44225851	DE
156	-50.31001	-27.5279109214	182.76	317.45	124.25	491	204.11981393	DE
260	-129.05001	-49.3499082218	261.5	351.7	124.25	930	235.30098689	DE

IDP - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 132,45 €

How many Biogen shares are in issue?

Biogen has 146.374.937 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 20,4B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 124,25 € to 219,70 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 12,94

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2,18

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9,68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1,63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
0S90Syros Pharmaceuticals Inc	0,162 € (100,00%)	264,82k
L09Lithium Energi Exploration Inc	0,018 € (56,52%)	1,5k
L7C2Windfall Geotek Inc	0,0145 € (52,63%)	2,71k
ZN80Hesai Group	21,80 € (47,30%)	1,87k
9AOAtico Mining Corp	0,0385 € (40,00%)	1,38k
POTAPortofino Resources Inc	0,0024 € (-53,85%)	1,3k
7KOCullinan Metals Corp	0,0062 € (-36,73%)	10k
V44Tearlach Resources Limited	0,0071 € (-33,02%)	2k
CNWCodon AG	0,0185 € (-30,19%)	8,1k
KHPKohls Corp	8,356 € (-25,37%)	267,11k
D7GNel ASA	0,2019 € (16,03%)	13,62M
E3BEutelsat Communications	6,835 € (-14,46%)	2,52M
POQ88 Energy Limited	0,0009 € (-10,00%)	2,35M
FMKEcograf Limited	0,0956 € (17,16%)	2,13M
LHADeutsche Lufthansa AG	7,46 € (-4,06%)	1,95M

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biogen Inc (IDP)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Biogen Inc

IDP Neueste Nachrichten

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

IDP - Frequently Asked Questions (FAQ)

Beweger

IDP Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biogen Inc (IDP) Börsenkurse

Biogen Inc (IDP)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Biogen Inc

IDP Neueste Nachrichten

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

IDP - Frequently Asked Questions (FAQ)

Beweger

IDP Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen